SCHEMBL31127751

SCHEMBL31127751

CO/N=C1\CCCc2cc(F)ccc21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.45
ALDH1A1 P00352 4/20 0.45
KMT2A Q03164 3/20 0.45
TDP1 Q9NUW8 1/20 0.45
CASP3 P42574 1/20 0.44
SENP8 Q96LD8 1/20 0.44
SENP7 Q9BQF6 1/20 0.44
SENP6 Q9GZR1 1/20 0.44
MAPK1 P28482 1/20 0.43
MEN1 O00255 2/20 0.40
LMNA P02545 3/20 0.37
MAOA P21397 1/20 0.36
MAOB P27338 1/20 0.36
NPC1 O15118 1/20 0.36
SRD5A1 P18405 1/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
PLA2G1B P04054 1/20 0.35
ATG4B Q9Y4P1 1/20 0.35
PKM P14618 1/20 0.35
KDM4E B2RXH2 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31127800 1.00 MAPT (0.45) MAPTALDH1A1KMT2ATDP1CASP3
SCHEMBL13606743 0.82 MAPT (0.45) MAPTALDH1A1KMT2ATDP1MAPK1
SCHEMBL27183548 0.81 HTT (0.50) MAPTALDH1A1KMT2ATDP1MAPK1
SCHEMBL31154857 0.81 MAPT (0.58) MAPTALDH1A1KMT2ATDP1MAPK1
SCHEMBL3823602 0.81 MAPT (0.58) MAPTALDH1A1KMT2ATDP1MAPK1
SCHEMBL34461285 0.81 MAOA (0.51) MAPTALDH1A1KMT2ATDP1MAPK1
SCHEMBL13019970 0.81 MAPT (0.58) MAPTALDH1A1KMT2ATDP1MAPK1
SCHEMBL31048348 0.81 MAPT (0.58) MAPTALDH1A1KMT2ATDP1MAPK1
SCHEMBL30846780 0.81 HTT (0.50) MAPTALDH1A1KMT2ATDP1MAPK1
SCHEMBL23977249 0.78 CYP11B2 (0.40) MAPTALDH1A1KMT2ATDP1CASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4688788-A1 PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS Pfizer Inc. (US) 2026-02-11 EP disclosed
US-12281127-B2 Pyrido[4,3-d]pyrimidine compounds PFIZER INC. (US) 2025-04-22 US disclosed
US-20250034173-A1 PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS PFIZER INC. (US) 2025-01-30 US disclosed
WO-2024209339-A1 PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS PFIZER INC. (US) 2024-10-10 WO disclosed
US-20240336631-A1 Pyrido[4,3-d]pyrimidine Compounds PFIZER INC. (US) 2024-10-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240336631-A1 Pyrido[4,3-d]pyrimidine Compounds DPYD, PNPO, TYMP MAPT 2869/4885ALDH1A1 436/4885KMT2A 3609/4885
US-12281127-B2 Pyrido[4,3-d]pyrimidine compounds DPYD, PNPO, TYMP MAPT 2869/4885ALDH1A1 436/4885KMT2A 3609/4885
US-20250034173-A1 PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS DPYD, PNPO, TYMP MAPT 2869/4885ALDH1A1 436/4885KMT2A 3609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.